OSI Pharmaceuticals Inc.
OSI Pharmaceuticals Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1992, the company has established itself as a leader in the development of innovative therapies, particularly in oncology and diabetes management. With a strong focus on research and development, OSI Pharmaceuticals has achieved significant milestones, including the successful launch of targeted therapies that address unmet medical needs. The company’s core products, such as its flagship oncology drug, exemplify its commitment to advancing patient care through cutting-edge science. OSI Pharmaceuticals is recognised for its unique approach to drug development, leveraging advanced technologies to enhance treatment efficacy. With a solid market position and a reputation for excellence, OSI Pharmaceuticals continues to make strides in improving health outcomes globally.
DitchCarbon Score
How does OSI Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
OSI Pharmaceuticals Inc.'s score of 18 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
OSI Pharmaceuticals Inc.'s reported carbon emissions
In 2009, OSI Pharmaceuticals Inc. reported total carbon emissions of approximately 191,000,000 kg CO2e for Scope 1, 201,000,000 kg CO2e for Scope 2, and 7,340,000 kg CO2e for Scope 3 emissions. This data highlights the company's significant carbon footprint, particularly in Scope 1 and Scope 2 emissions, which are primarily associated with direct operations and energy consumption, respectively. As of the latest information, OSI Pharmaceuticals has not established specific reduction targets or initiatives aimed at decreasing their carbon emissions. This lack of defined climate commitments may reflect a broader industry context where many pharmaceutical companies are increasingly focusing on sustainability and emissions reduction strategies. Overall, while OSI Pharmaceuticals has disclosed its emissions data, the absence of reduction targets suggests an opportunity for the company to enhance its climate commitments and align with industry standards for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2009 | |
|---|---|
| Scope 1 | 191,000,000 |
| Scope 2 | 201,000,000 |
| Scope 3 | 7,340,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
OSI Pharmaceuticals Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
